CUSIP 75886F107
REGN
latest 13F · 2026-Q1
Recent filings
47
Fund-manager holders (13F)
5
Last activity
Mar 31, 2026
Price chart
Every entry below is an auto-generated factual summary of a public filing or disclosure. Not investment advice. Verify before acting.
What they're saying
Letter2Q26 Partners Fund Commentary
Mason HawkinsLongleaf warns markets have reached speculative extremes, with CAPE at historic highs and AI-driven multiples disconnecting from real FCF.
“Regeneron – Healthcare company Regeneron was a detractor in the quarter after disappointing trial results for one of its pipeline drugs.”
Jun 30, 2026
Letter4Q25 Partners Fund Commentary
Mason HawkinsSoutheastern warns late-bull momentum mirrors 1987/1999, while portfolio shifts to ~45% defensive/cash weighting.
“We continue to like the company's strong position in allergic diseases (DUPIXENT) and oncology (LIBTAYO and others). We believe the market focuses too much on EYLEA”
Dec 31, 2025
Letter3Q25 Partners Fund Commentary
Mason HawkinsLongleaf warns Mag 7 valuations are disconnected from FCF growth, while its own portfolio trades at ~10x FCF with multiple catalysts ahead.
“Regeneron (4.9% portfolio weight): After a slow start to our holding period this year, Regeneron has found its footing and grown its value per share back to above where we started the year”
Sep 30, 2025
Smart-money holders
| Investor | Shares | Market value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness | 1,231,008 | $946.0M | — | 2026-Q1 |
| Michael Burry | 215,000 | $112.9M | — | 2025-Q2 |
| Mason Hawkins | 130,662 | $101.0M | — | 2026-Q1 |
| Jeremy Grantham |
Recent flows
Mar 31, 2026
Mar 31, 2026
Mar 31, 2026
Mar 31, 2026
Dec 31, 2025